02421nas a2200397 4500000000100000008004100001653002200042653001600064653002600080653001600106653000900122653001200131653002300143653001100166653001100177653003000188653002100218653001000239653002200249653000900271653001000280653001500290100001400305700001600319700002000335700001700355700001400372700001700386700001300403245006900416856005100485300001100536490000700547520145500554022001402009 2013 d10aTreatment Outcome10aSex Factors10aRetrospective Studies10aMiddle Aged10aMale10aleprosy10aLeprostatic Agents10aHumans10aFemale10aDrug Therapy, Combination10aChild, Preschool10aChild10aAged, 80 and over10aAged10aAdult10aAdolescent1 aDupnik KM1 aCardoso FJR1 aDe MacĂȘdo ALBB1 aDe Sousa ILC1 aLeite RCB1 aJeronimo SMB1 aNobre ML00aIntolerance to leprosy multi-drug therapy: more common in women? uhttps://leprosyreview.org/article/84/3/20-9218 a209-180 v843 a
OBJECTIVES: The objective was to characterise and identify potential risk factors for intolerance to multi-drug leprosy therapy (MDT) which prompted a medication change in a leprosy referral centre in northeastern Brazil.
DESIGN: A retrospective chart review of leprosy patients treated at a state referral centre for leprosy in Natal, Rio Grande do Norte, Brazil was completed. Chart review focus was on adverse effects necessitating modification of MDT regimen.
RESULTS: Six hundred and twelve records were reviewed with detection of 91 (14.8%) adverse effects with associated change in MDT regimen. The most common recorded causes of medication intolerance were anemia (8.7%), headache (4.2%), cyanosis (1.8%), and gastrointestinal symptoms (1-6%). Both female gender (OR = 2.63) and age less than 42 years old (OR = 2.7) remained risk factors for MDT intolerance in a multivariate model including gender, age, and WHO regimen type. With intolerance due to anemia as the outcome, female gender (OR = 2.36) and age less than 42 years (OR = 1.86) were associated.
CONCLUSIONS: In this study, female gender and younger age were associated with greater risk of medication intolerance and medication intolerance related to anemia. These findings have important operational implications for drug intolerance monitoring during therapy for leprosy.
a0305-7518